Biosergen AS acquires innovation award from The Research Council of Norway (BIA)

Biosergen AS acquires innovation award from The Research Council of Norway (BIA)

The Trondheim based biotech company Biosergen AS, developing new drugs based on cutting edge approach ‘engineered biosynthesis’, announced today receiving of the BIA innovation award from the Research Council of Norway. 181 companies submitted applications for BIA funding and Biosergen AS belongs to the 50 awarded ones.
Based on the unique expertise in biosynthetic engineering, Biosergen AS is currently running a development program for systemic fungal infections, with a candidate drug in pre-clinical development. Anders Kronström, the CEO of Biosergen AS commented: “This innovation grant means a lot for our research and also for patients worldwide suffering from diseases caused by systemic fungal infections. It will directly strengthen our opportunities to turn our innovation efforts into improved treatments.”
Torsten Goesch, Biosergen AS Chairman of the Board and Partner of Rosetta Capital Ltd, added: “We also see this award as an essential recognition to our research and the unique capabilities which our scientists and collaboration partners possess. No doubt, this is an appreciation which we proudly share with the entire Nordic Life Science community.”
To learn more visit the Biosergen AS webpage. 
For questions, please contact: anders.kronstrom@biosergen.se
_________________________________________________________________________________
About Biosergen AB:
Biosergen AS is a biotech company developing new drugs based on cutting edge biosynthetic engineering of natural products, combined with chemical synthesis. Established in 2004, the company is based in Trondheim, Norway and focuses its innovative research on fighting systemic fungal infections. www.biosergen.se

MEDIA RELEASE

11 February 2016